ストックスクリーナーアプリを入手
1.79
7.01%
-0.135
前日終値:
$1.925
開ける：
$1.94
24時間の取引高:
1.38M
Relative Volume:
1.03
時価総額：
$214.48M
収益：
$6.65M
当期純損益:
$-136.32M
株価収益率:
-1.5596
EPS:
-1.1477
ネットキャッシュフロー:
$-112.04M
1週間 パフォーマンス:
-17.89%
1か月 パフォーマンス:
-26.64%
6か月 パフォーマンス:
+30.66%
1年 パフォーマンス:
+16.23%
1日の値動き範囲:
$1.78
$1.975
1週間の範囲:
$1.78
$2.18
52週間の値動き範囲:
$0.95
$3.23
Fate Therapeutics Inc Stock (FATE) Company Profile
名前
Fate Therapeutics Inc
セクター
電話
858.875.1803
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.79 | 214.48M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-05-19 | 再開されました | Jefferies | Buy |
| 2025-10-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-11-18 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-06-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
| 2023-01-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-01-06 | ダウングレード | Cowen | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | ダウングレード | Stifel | Buy → Hold |
| 2023-01-06 | ダウングレード | Truist | Buy → Hold |
| 2023-01-06 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 開始されました | Goldman | Sell |
| 2022-11-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-08-18 | 再開されました | Wells Fargo | Overweight |
| 2022-07-28 | 開始されました | Needham | Hold |
| 2022-07-11 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 開始されました | Robert W. Baird | Neutral |
| 2022-02-11 | 再開されました | BMO Capital Markets | Market Perform |
| 2021-12-15 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-12-07 | 開始されました | Cowen | Outperform |
| 2021-11-09 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-26 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-07 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Jefferies | Buy |
| 2021-02-26 | 開始されました | BofA Securities | Buy |
| 2021-02-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-02-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-27 | 再開されました | H.C. Wainwright | Neutral |
| 2020-05-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-09 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 繰り返されました | Mizuho | Buy |
| 2019-12-09 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-06 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 開始されました | Stifel | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-07-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 開始されました | Oppenheimer | Outperform |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-06-07 | 開始されました | ROTH Capital | Neutral |
| 2019-05-31 | 開始されました | Guggenheim | Buy |
| 2019-05-24 | 再開されました | Citigroup | Buy |
| 2019-03-28 | 開始されました | SVB Leerink | Outperform |
| 2019-01-03 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 開始されました | Jefferies | Buy |
| 2018-08-01 | 開始されました | Citigroup | Buy |
| 2018-03-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
すべてを表示
Fate Therapeutics Inc (FATE) 最新ニュース
Fate Therapeutics, Inc. Stock 12‑Month Price Target Cut to $6.07, Implies 215% Upside - TradingView
Fate Therapeutics stock stands 97.96 percent higher year to date - ad-hoc-news.de
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance Singapore
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance UK
Fate Therapeutics appoints Jamie Harrell to lead commercial strategy By Investing.com - Investing.com Nigeria
Fate Therapeutics appoints Jamie Harrell to lead commercial strategy - Investing.com
Fate Therapeutics appoints Jamie Harrell to lead commercialization By Investing.com - Investing.com South Africa
Fate Therapeutics appoints Jamie Harrell to lead commercialization - Investing.com
Fate Therapeutics appoints Jamie Harrell to lea... - Pluang
Fate Therapeutics appoints Jamie Harrell to lead commercialization By Investing.com - Investing.com Canada
Fate Therapeutics names Jamie Harrell SVP of commercial operations - StreetInsider
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies - GlobeNewswire Inc.
Fate Therapeutics Appoints Jamie Harrell as Senior Vice - GlobeNewswire
Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics. - Stock Titan
Fate Therapeutics Appoints Jamie Harrell as Senior Vice - GlobeNewswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Has Consensus Target Price of $5.90 - MarketBeat
Fate Therapeutics grants employee awards: what it means for Fate Therapeutics stock - AD HOC NEWS
Fate Therapeutics stock adds two Q4 conference dates - AD HOC NEWS
Fate Therapeutics stock gained 4.74 percent on October 5 - AD HOC NEWS
Fate Therapeutics (NASDAQ:FATE) Shares Cross Above 50-Day Moving AverageTime to Sell? - marketbeat.com
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance Australia
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Two new hires at Fate Therapeutics get stock awards that vest over four years if they stay - stocktitan.net
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics, Inc. (F6T.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fate Therapeutics, Inc. (FATE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences - GlobeNewswire Inc.
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences - GlobeNewswire
FRAUD AND MANIPULATION—S.D. Cal.: Pharma company ducks securities fraud claim for lack of loss causation - VitalLaw.com
Gross profit of Fate Therapeutics, Inc. – HAN:F6T - TradingView
Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial - Yahoo Finance
Fate Therapeutics receives $15m CIRM grant for lupus trial - Investing.com
Fate Therapeutics receives $15m CIRM grant for lupus trial By Investing.com - Investing.com Canada
Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis - Quiver Quantitative
Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis - Quiver Quantitative
Fate Therapeutics Announces Receipt of California Institute - GlobeNewswire
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN - Yahoo Finance
Fate Therapeutics Inc (F6T.MU) stock price, news, quote and history - Yahoo Finance UK
Longeveron slides 59% after-hours from stem cell therapy study failure - Mugglehead Investment Magazine
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - GlobeNewswire
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - Yahoo Finance
A study explores cell therapy without preparatory chemotherapy. Fate will present four at ACR. - stocktitan.net
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts - MarketBeat
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Nigeria
Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com Canada
Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com UK
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com South Africa
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Canada
Fate Therapeutics to Present FT819 and FT839 Data at CCR West Meeting, Highlighting Safety and Efficacy in Autoimmune Disease - Quiver Quantitative
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com UK
Fate Therapeutics Inc (FATE) 財務データ
収益
当期純利益
現金流量
EPS
Fate Therapeutics Inc (FATE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO |
Aug 04 '26 |
Sale |
2.46 |
43,947 |
108,101 |
591,815 |
| TAHL CINDY | Officer |
Aug 04 '26 |
Proposed Sale |
2.46 |
38,800 |
95,405 |
0 |
| Valamehr Bahram | Officer |
Aug 04 '26 |
Proposed Sale |
2.46 |
43,947 |
108,101 |
0 |
| TAHL CINDY | See Remarks |
May 20 '26 |
Sale |
1.88 |
25,590 |
48,084 |
628,155 |
| Valamehr Bahram | President and CEO |
May 20 '26 |
Sale |
1.88 |
28,946 |
54,482 |
635,762 |
| Valamehr Bahram | Officer |
May 20 '26 |
Proposed Sale |
1.88 |
28,946 |
54,482 |
0 |
| TAHL CINDY | Officer |
May 20 '26 |
Proposed Sale |
1.88 |
25,590 |
48,084 |
0 |
| TAHL CINDY | See Remarks |
May 06 '26 |
Option Exercise |
1.25 |
166,664 |
207,997 |
653,745 |
| EPSTEIN ROBERT S | Director |
May 05 '26 |
Option Exercise |
1.69 |
25,000 |
42,250 |
36,331 |
| RASTETTER WILLIAM H | Director |
May 05 '26 |
Option Exercise |
1.69 |
25,000 |
42,250 |
36,331 |
4.22%
大文字化:
|
ボリューム (24 時間):